Colon-cancer liver metastasis is effectively targeted by recombinant methioninase (rMETase) in an orthotopic mouse model

Background: Colorectal cancer liver metastasis (CCLM) is the most frequent cause of death of colorectal cancer. Development of novel new effective therapy is needed for CCLM patients to improve outcome. The aim of the present study was to investigate the efficacy of recombinant methioninase (rMETase) on a CCLM orthotopic mouse model of liver metastasis established using the human colon cancer cell line HT29 expressing red fluorescent protein (RFP). Materials and Methods: Orthotopic CCLM nude mouse models were randomized into two groups: control group (n = 6, PBS 200 & mu;l, i.p., daily); rMETase group (n = 6, 100 units/200 & mu;l, i.p., daily). Tumor volume was measured on day 0 and day 15. Body weight was measured twice a week. All mice were sacrificed on day 15.Results: rMETase significantly inhibited the increase of the liver metastasis as determined by RFP fluorescence area and intensity (p = 0.016 and 0.015, respectively). There was no significant difference of body weight between either group on any day.Conclusions: The present study suggests that rMETase has future potential therapy for CCLM in the clinic.

Automated summary

The efficacy of recombinant methioninase (rMETase) on a mouse model of colorectal cancer liver metastasis was investigated in this study. The results showed that rMETase significantly inhibited the increase of liver metastasis. Therefore, rMETase may have future potential as a therapy for colorectal cancer liver metastasis.